ClinicalTrials.gg
Sign In
Enrolling by invitationNCT06330974FinnATOPYUpdated Oct 27, 2026

Allergy, Asthma, and Atopic Eczema in Finland

An observational study in Asthma, Asthma in Children and Allergy, sponsored by Tampere University. Enrolling by invitation at 1 site in Finland. Per ClinicalTrials.gov, last updated 2026-10-27.

Sponsored by Tampere University · Observational

Updated Oct 27, 2026Now Enrolling by invitationStart date moved+3 moreGo to Updates ↓
Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
1,600,000
Sex
All
01

Study summary

The summary is available at --> https://www.finnatopy.fi/summary

Read the detailed description

Aims and objectives ---> https://www.finnatopy.fi/aims-and-objectives Methods ---> https://www.finnatopy.fi/methods

02

Conditions studied

  • Asthma
  • Asthma in Children
  • Allergy
  • Rhinitis, Allergic
  • Atopic Dermatitis
  • Allergen Immunotherapy
03

In context

Asthma

4,841 studies on the registry are indexed under Asthma; 600 are open to participants now.

This study's planned enrollment of 1,600,000 is above the median of 158 across 1,250 observational studies indexed under Asthma.

Browse Asthma studies →

Lead sponsor

Tampere University is the lead sponsor of 63 studies on the registry; 11 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

https://www.finnatopy.fi/methods

Eligibility criteria

Inclusion/Exclusion Criteria ---> https://www.finnatopy.fi/methods

05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
1,600,000 participants (estimated)
Target follow-up
7 Years
Patient registry
Yes

Groups and cohorts

  • Atopic

    Patientes with any atopic condition (g.e., asthma, atopic dermatitis, IgE-mediateid allergy)

    Other: No intervention · Other: No Intervention: Observational Cohort

  • Control group - migrane

    Patients with migrane

    Other: No intervention · Other: No Intervention: Observational Cohort

  • Control group - celiac disease

    Patients with celiac disease

    Other: No intervention · Other: No Intervention: Observational Cohort

  • Control group - UTI

    Patients with urinary tract infection

    Other: No intervention · Other: No Intervention: Observational Cohort

  • Control group - LRTI

    Patients with lower respiratory tract infection

    Other: No intervention · Other: No Intervention: Observational Cohort

  • Control group - bronchitis

    Patients with acute bronchitis

    Other: No intervention · Other: No Intervention: Observational Cohort

Interventions

  • OtherNo intervention

    No intervention

  • OtherNo Intervention: Observational Cohort

    No intervention

06

What researchers measure

Primary outcomes

  1. Epidemiology of atopic diseases and allergic sensitization profiles in Finland

    Incidence and prevalence of asthma, specific IgE sensitization, atopic dermatitis, allergic rhinitis

    Time frame: 7 years

  2. Burden of atopic diseases (allergies, asthma, and atopic eczema) as well as comorbidities in Finland

    Morbidity, sick leaves, medication use, costs and expences

    Time frame: 7 years

  3. Evaluate and improve the current use of diagnostic tests for atopic diseases

    Diagnostic practices, tests for allergic sensitization, lung function tests, and other laboratory measures.

    Time frame: 7 years

  4. Use and effectiveness of allergen immunotherapy in real world setting

    Real world evidence data using specific cohorts

    Time frame: 7 years

  5. Direct and indirect costs related to atopic diseases and comorbidities

    All costs, including sick leaves, absenteeism, laboratory costs, other diagnisteic tests, etc.

    Time frame: 7 years

07

Study locations

1 site
08

References and documents

Related links

Individual participant data

Plan to share: Undecided

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2026 (actual). Primary completion is estimated for Dec 2032, 74 months after the start.

Of 364 non-industry observational studies under Asthma, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 97. This study's planned 74 months is above that.

Counting every sponsor, half of 454 studies reached it within 36 months; a quarter within 18 and three quarters within 82.

Start moved twice since we started tracking on Sep 25, 2026: Oct 2024 → Oct 2026, last on Oct 27, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 12, 2024
First posted
Mar 26, 2024
StartActual
Oct 1, 2026was Oct 2024
Primary completionEst.
Dec 2032
CompletionEst.
Dec 2034
Last update
Oct 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Enrolling by invitation
changed Oct 27, 2026
Start date
Oct 2024→Oct 1, 2026 (actual)
moved 2 times, Oct 15, 2026 – Oct 27, 2026
Enrollment
2000000→1600000
Oct 27, 2026
Eligibility
Revised
Oct 15, 2026
Interventions
Added No Intervention: Observational Cohort
Oct 15, 2026
Contact
No study contact listed any more: removed p•••@tuni.fi · •••1103
Oct 27, 2026
Show all 2 updates
  1. Oct 27, 2026
    Not yet recruiting→Enrolling by invitation
    Start date Dec 1, 2026→Oct 1, 2026 (now actual)
    Enrollment 1200000→1600000
    Contact No study contact listed any more: removed p•••@tuni.fi · •••1103
  2. Oct 15, 2026
    Start date Oct 2024→Dec 1, 2026
    Enrollment 2000000→1200000
    Eligibility Revised
    Interventions Added No Intervention: Observational Cohort
    + 3 other changes: verification date, references and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06330974
Lead sponsor
Tampere University
Collaborators
Professor Lauri Lehtimäki, Professor Mika Mäkelä, Professor Sanna Toppila-Salmi, Professor Ilkka Junttila
Responsible party
Peter Csonka (MD, PhD, Associate professor of pediatrics, Tampere University) — Principal investigator
First posted
Mar 26, 2024
Start date
Oct 1, 2026
Primary completion
Dec 2032 (estimated)
Completion
Dec 2034 (estimated)
Last update
Oct 27, 2026

Study contacts

Péter Csonka
principal investigator · Tampere University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Asthma →

Other studies from this sponsor

Tampere University

Start the discussion